|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on January 23, 2003; DOI 10.1182/blood-2002-08-2673.
IMMUNOBIOLOGY
From the Department of Biomedical Engineering,
Northwestern University, Evanston, IL; the Pediatric Brain Tumor
Research Program, Department of Neurological Surgery, Northwestern
University Medical School and Children's Memorial Institute of
Education and Research, Chicago, IL; Robert H. Lurie Comprehensive
Cancer Center, Northwestern University Medical School, Chicago, IL; and
the Department of Microbiology-Immunology, Northwestern Medical School,
Chicago, IL.
The formation of terminally differentiated plasma cells represents
the critical final step in B-cell differentiation. In this study,
utilizing oligonucleotide microarray analysis, we describe the highly
specialized genetic profile exhibited by terminally differentiated
plasma cells. A total of 1476 known genes were differentially expressed
by plasma cells compared with B cells. Plasma cells displayed an
up-regulation, induction, or a selective retention of a unique
constellation of transcription factors, including members of the AP-1,
nuclear factor- Plasma cells, which constitute the final stage of
B-cell differentiation, are specialized terminally differentiated cells with one primary function, the secretion of antibody. Recent work has
begun to reveal some of the factors that regulate plasma cell formation
and function. The transcription factors XBP-1, Blimp-1, and IRF-4 have
each been demonstrated to be critically involved in plasma cell
differentiation.1-4 Furthermore, B-cell transcription factors Pax5 and BCL-6, which can repress transcription of XBP-1 and
Blimp-1, respectively, are down-regulated during plasma cell differentiation.5-7 Recent analysis has provided important
information regarding the critical role of Blimp-1 in regulating plasma
cell gene expression, including, among other aspects, the repression of
Pax5, BCL-6, and B-cell transcription factors Spi-B and
Id3.8,9
Mice deficient in both E- and P-selectin display extremely elevated
serum immunoglobulin G (IgG) levels and severe cervical lymphadenopathy consisting of expanded numbers of lymphocytes, including numerous plasma cells.10 Previously, we have
demonstrated that the cervical lymph nodes of these mice provide a
unique system for the investigation of B-cell differentiation.
Furthermore, we described the purification of significant numbers of
B220 Although recent advances have provided insight into plasma cell
biology, many aspects of plasma cell function have yet to be
determined, including many factors that modulate plasma cell differentiation and function in vivo. Plasma cell gene expression profiles potentially represent crucial information regarding
unidentified transcription factors and signaling molecules important in
plasma cells, the adhesion molecules, and secreted factors that
regulate the interaction of plasma cells with their microenvironment as well as mechanisms of terminal differentiation. Here we report gene
expression profiling of B220 Mice
Cell isolation
Complementary RNA probe preparation and chip hybridization Total RNA was isolated from either plasma cells or B cells using Trizol (Life Technologies, Carlsbad, CA), followed by an additional purification with the RNeasy Mini Kit (Qiagen, Valencia, CA). Double-stranded cDNA was synthesized using a (dT)24 primer containing a T7 RNA polymerase initiation site (Genset, La Jolla, CA) and the Superscript Double Stranded cDNA Synthesis Kit (Life Technologies), with 5 to 10 µg total RNA as a template. Following phenol-chloroform extraction of the cDNA, biotinylated cRNA was generated using the Bioarray HighYield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY) and purified using the RNeasy Mini Kit (Qiagen). A total of 15 µg labeled cRNA was fragmented according to Affymetrix procedures, and the chip hybridization was performed as described.12 Briefly, the cRNA with hybridization controls was hybridized to the murine chip, MG-U74 AV2, according to the Affymetrix protocol. Staining was performed in the GeneChip Fluidics station, and chips were scanned in the Affymetrix GeneChip scanner. Three replicates were performed for both plasma cells and surface IgM+ B cells, each from independent cell preparations.Data analysis Gene expression analysis was performed using Gene Spring (Silicon Genetics, Redwood City, CA). Per chip and per gene normalizations of the expression values (average differences) were executed with Gene Spring, and normalized expression values less than 0.01 were set to 0.01. Gene trees were generated by hierarchical clustering using the standard correlation (Pearson correlation around 0) with a separation ratio of 0.5 and a minimum distance of 0.001.To eliminate genes from the analysis that were not expressed by either plasma cells or B cells, 3 categories of interest were formulated using the present/absent calls generated by the Affymetrix Microarray Suite 4.0. These categories were the following: present in plasma cells/absent in B cells, absent in plasma cells/present in B cells, and present in both cell types. A marginal call was considered absent for these purposes. The cutoff for inclusion in these groups was that 5 of 6 samples had to correspond with the category criteria. For example, to be included in the present in plasma cells/absent in B cells group, a present call in at least 2 plasma cell replicates with an absent call in all 3 B-cell replicates, or a present call in all 3 plasma cell replicates with an absent call in at least 2 B-cell replicates was required. A gene was classified as differentially expressed in plasma cells and B cells if it was (1) among one of these categories and (2) exhibited a statistically significant (P < .05, Mann-Whitney test) and (3) exhibited 2-fold or greater change in the mean expression level. When multiple oligo sets for one gene appeared on the chip, the set derived from the complete cDNA sequence was used. If multiple cDNA-derived sets appeared on the chip, a representative result is shown. A complete list of all the genes examined and all values for each replicate is available on the Blood website; see the Supplemental Data link at the top of the online article. SDS-PAGE and Western Blot analysis Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis of plasma cell and B-cell lysates were performed as described.11 Cell lysates were made from equal numbers of cells with the following high-salt RIPA lysis buffer: 50 mM Tris (tris(hydroxymethyl)aminomethane) (pH 8), 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, and 1 mM EDTA (ethylenediaminetetraacetic acid), with protease inhibitors. Rabbit antimouse TBP antiserum was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish peroxidase-conjugated antirabbit and antimouse IgG antibodies were purchased from Biosource, and nitrocellulose membranes were developed using enhanced chemiluminescence reagents (Amersham Biosciences, Arlington Heights, IL). The murine plasmacytoma cell line, J558, was used as a positive control for TBP.Real-time quantitative RT-PCR Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was performed using the 7700 sequence detector system as previously described.12 Twenty-five nanograms of total RNA isolated from plasma cells or B cells was used as a template in a 50-µL RT-PCR reaction with the following components: 1 × TaqMan buffer, 5 mM MgCl2, 0.3 mM deoxyadenosine monophosphate (dATP), 0.3 mM deoxycytidine triphosphate (dCTP), 0.3 mM deoxyguanosine triphosphate (dGTP), 0.6 mM deoxyuridine triphosphate (dUTP), 0.1 µM forward and reverse primers, 0.1 µM TaqMan probe, 1.25 units AmpliTaq Gold, 20 units RNase inhibitor, and 12.5 units murine leukemia virus (MuLV) reverse transcriptase. The primers and TaqMan probes were designed using Primer Express software (Perkin Elmer Life Sciences, Shelton, CT), and the sequences are listed in the methods document in the supplemental data. The primers were purchased from Integrated DNA Technologies, and the TaqMan probes were purchased from MegaBases. The cycling parameters were 48°C for 30 minutes, then 95°C for 15 minutes, followed by 40 cycles at 95°C for 15 seconds and 59°C for 1 minute. Rn represents the reporter signal with the baseline
subtracted, and the threshold cycle (CT) is the cycle at
which Rn crosses the threshold for the given sample. The default
threshold was used, which is set at 10 standard deviations above baseline.
Plasma cells and IgM+ B cells display highly distinct gene expression profiles The gene expression profile of plasma cells was compared with surface IgM+ B cells using the Affymetrix murine oligonucleotide array, MG-U74 AV2. With this array, the expression of 12 422 genes was examined, and 3 replicates of each cell type were performed. Hierarchical clustering of these genes demonstrates the high degree of reproducibility of the replicates. As expected, the gene expression profiles of IgM+ B cells and plasma cells were extremely distinct (Figure 1). Furthermore, it was clear from initial observations that plasma cells in general lose expression of many more genes than they gain. Genes were initially categorized based on the present and absent determinations: 396 genes were consistently expressed in plasma cells although absent in B cells, whereas 1395 genes were absent in plasma cells and expressed in B cells, and 3676 genes were expressed in both cell types. Genes were considered altered in plasma cells if they were (1) among one of these categories and additionally displayed (2) a statistically different and (3) 2-fold or greater change in mean expression. With these criteria, 2469 genes were determined to be significantly altered in plasma cells, which included 1476 known genes and 993 unknown expressed sequence tags (ESTs). The altered expression in plasma cells of numerous genes, including Blimp-1, IRF-4, XBP-1, Pax5, CIITA, BCL-6, syndecan-1, CD43, CD19, CD22, MHC class II, CD37, CD79A, L-selectin, CD38, and CD44, were all consistent with previous findings for plasma cells,9,11,13 confirming the fidelity of the analysis.
Plasma cells express a unique constellation of transcription factors Among the many genes differentially expressed in plasma cells and IgM+ B cells were numerous transcription factors (Figure 2). As expected and mentioned above, these included the transcription factors Blimp-1, IRF-4, and XBP-1, which were increased in plasma cells 29.4-, 4.0-, and 17.2-fold, respectively, and have been previously identified as important in plasma cell differentiation.1,2,4 In addition, the loss of multiple B-cell transcription factors in plasma cells, including CIITA, BCL-6, c-myc, EBF, Stat6, and Pax5 (Figure 2), were all consistent with previous findings and with the role of Blimp-1 in repression of these genes.9,14,15 Alterations in expression of several genes were confirmed by quantitative RT-PCR, and these results are shown in Table 1 and Figure 3A. These genes included, among others, XBP-1, Blimp-1, Stat6, and CIITA.
Additionally, these IgG plasma cells also displayed an induction, loss, or selective retention of specific members of multiple other transcription factor families. Among the AP-1 family, c-jun was induced 23.0-fold in plasma cells, and c-fos and fos-B were both up-regulated 5.1-fold and 4.5-fold, respectively (Figure 2). In contrast, jun-B was down-regulated 13.3-fold in plasma cells (Figure 2), whereas jun-D was retained equally in all samples (supplemental data). This altered expression of AP-1 proteins is particularly interesting considering recent data demonstrating that BCL-6 represses Blimp-1 by inhibiting AP-1 transcriptional activation of Blimp-1.16 Furthermore, the plasma cells demonstrated a selective down-regulation
of several components of the nuclear factor-
Examination of mice with lymphocytes deficient in both nuclear factor of activated T cells c1 (NFATc1) and NFATc2 suggested an intrinsic role for these transcription factors in B-cell function, with expanded numbers of plasma cells and elevated IgG1 and IgE serum levels, despite impaired T-cell effector function.19 The plasma cells examined here demonstrate a down-regulation of NFATc1 mRNA as well as NFATc3 (Figure 2). The down-regulation of NFATc1 was also confirmed by quantitative RT-PCR (Table 1). However, NFATc2 is maintained in plasma cells equal to surface IgM+ B cells (supplemental data). Although not required for plasma cell differentiation,19,20 the selective retention of NFATc2 mRNA described here suggests a possible role for NFATc2, nonredundant with NFATc1, in plasma cell function. Conversely, the selective loss of NFATc1 and NFATc3 may be important in plasma cell function through the loss of certain inhibitory functions. The plasma cells demonstrated a loss in c-myc expression, consistent
with Blimp-1 expression by these cells (Figure 2)11 and
previous results that illustrate the role of Blimp-1 in c-myc repression.15 In addition to the loss of c-myc, the c-myc
dimerization partner Max was down-regulated in plasma cells 5.9-fold,
and Mxi1, a member of the Mad family of c-myc antagonists, was
up-regulated in plasma cells 3.6-fold (Figure 2). The c-myc adaptor
protein BIN1 was also lost in plasma cells (Figure 2). In contrast to the up-regulation of Mxi1, another c-myc antagonist, Mnt/ROX, was lost
in plasma cells (Figure 2). Unlike Mxi1, which interacts only with Max,
Mnt can interact with Max and the Max-like protein, Mlx.21
Interestingly, Mlx and the Mad protein Mad4 were retained in plasma
cells equal to B cells (supplemental data), suggesting that they could
possibly play a role in plasma cell function. Although further analysis
is certainly required to determine the mechanism, this expression
profile suggests a cooperative effect of additional members of the
Myc/Mad/Max system in the antagonism of c-myc function in plasma cells.
Furthermore, as demonstrated previously, the repression of c-myc
is necessary but not sufficient for plasma cell terminal
differentiation.22 Accordingly, the plasma cells also
displayed a down-regulation in many additional genes involved in
cell cycle control and proliferation (Table 2).
Octamer site binding transcription factors have been implicated in
B-cell function, including the transcriptional activity of Ig promoters
and the 3' C In addition to the multiple specific transcription factors whose expression was altered in plasma cells, plasma cells also demonstrated expression changes in components of the basal transcription apparatus as well as in several transcriptional cofactors that play critical roles in the transcription of numerous genes. Among these were histone deacetylase-1 (HDAC1), the TATA box binding protein (TBP), the large subunit of RNA polymerase II (RPB1), and the coactivator PCAF, which all displayed reduced expression in plasma cells (Figure 2). Thus, consistent with the highly specialized function of the plasma cell, plasma cells may exhibit unique general transcription mechanisms. Although unexpected, a down-regulation of TBP mRNA in plasma cells was confirmed by quantitative RT-PCR (Figure 3A and Table 1), and TBP protein levels were sharply reduced in plasma cells as well (Figure 3B). In contrast, mRNA encoding TBP-like factor (TLF) was expressed by both the plasma cells and B cells examined here (supplemental data), and TBP and TLF can differentially regulate the transcription of certain genes.26 Consequently, further analysis is required to elucidate the role of decreased TBP levels and the possible function of TLF in primary plasma cells. Additionally, 3 components of the RNA polymerase I complex important in rRNA transcription, the transcription factors UBF, TAFI48, and TAFI95, also showed a reduced expression in plasma cells (Figure 2). A down-regulation of UBF was also confirmed by quantitative RT-PCR (Table 1). Down-regulation of these components and concomitant decreases in rRNA transcription have been observed previously upon cellular differentiation with cell cycle exit. For example, UBF, TAFI48, and TAFI95 down-regulation was associated with the differentiation of F9 embryonal carcinoma cells into parietal endoderm.27 Strikingly, overall TBP protein was also reduced following F9 cell differentiation.27 Furthermore, decreased rRNA transcription was correlated with the down-regulation of UBF during the terminal differentiation of skeletal muscle cells.28 Consequently, similar to other terminally differentiated cell types, the terminal differentiation of plasma cells is associated with a reduction in the expression of TBP and with a decrease in ribosomal RNA transcription. Plasma cells show alterations in many receptors and signaling molecules, including cytokine receptor-associated factors and members of the Wnt and Notch pathways Plasma cells and B cells displayed numerous differences in the expression of receptors and signaling molecules, and a selection of these genes is shown in Figure 4. For example, IRS2, which plays a role in the signaling via several receptors, including the interleukin-4 (IL-4) receptor and the insulin-like growth factor-1 (IGF-1) receptor,29,30 was induced in plasma cells (Figure 4). The IGF-1 receptor itself was also induced, consistent with results obtained with multiple myeloma cells.31 The presence of both the IGF-1 receptor and IRS2 suggests a possible role of this signaling pathway in primary plasma cell function. In contrast, the receptor for IL-4 as well as receptors for the cytokines IL-10, IL-17, and the / and  interferons were lost or
down-regulated in plasma cells (Figure 4). Among the Janus kinase (Jak)
family, Jak1 and Jak2 were lost in plasma cells (Figure 4), whereas
Jak3 was expressed equally in both cell types (supplemental data). In
accordance with Stat6 as a target of Blimp-1-mediated
down-regulation,9 Stat6 was lost in the plasma cells
examined here (Figure 2 and Table 1). In addition, Stat4 and Stat5b
were also lost (Figure 2), whereas Stat1 and Stat3 were retained at
levels equal to B cells (supplemental data).
In addition to the selective retention of Stat3 itself, the plasma
cells exhibited a loss in the expression of the protein inhibitor of
activated Stat3 (PIAS3) (Figure 4). In contrast, the protein inhibitor
of activated Stat1 (PIAS1) was expressed equally in plasma cells and B
cells (supplemental data). Strikingly, mRNA encoding the suppressor of
cytokine signaling-3 (SOCS3), which can inhibit IL-6 receptor
signaling through Stat3,32 also displayed a reduced
expression in plasma cells (Figure 4). This down-regulation of SOCS3
expression in plasma cells was confirmed by quantitative RT-PCR (Figure
3A and Table 1). On the contrary, SOCS2, which can be induced by IL-6
signaling but does not effectively inhibit IL-6
signaling,32,33 was induced in plasma cells. Additionally, the chaperone protein Grp58, which has been shown to interact with
Stat3,34 was up-regulated in plasma cells. The signaling component of the IL-6 receptor, gp130, was expressed by both B cells
and plasma cells and displayed a 1.8-fold statistically significant
increase in plasma cells (supplemental data). In contrast, the IL-6
receptor Several components of the Wnt signaling pathway also displayed an
altered expression in plasma cells relative to B cells. In the absence
of a Wnt signal, Interestingly, the plasma cells also demonstrated alterations in the
mRNA levels of several secreted factors, including an induction of
VEGF-A (Table 3). The expression of VEGF
by plasma cells has previously been associated with multiple myeloma,
where an autocrine loop of vascular endothelial growth factor
(VEGF) signaling can stimulate myeloma cell
proliferation.48 In contrast to myeloma, the VEGF receptor
Flt-1 was not expressed by the primary plasma cells examined here (nor
was the receptor KDR), suggesting that an autocrine loop is not present
in primary plasma cells. VEGF expression by plasma cells has also been
demonstrated in the lymph nodes of patients with Castleman disease but
not in normal lymph nodes.49 Recently, it was demonstrated
that VEGF gene expression can be induced in B-cell lines by the
introduction of Blimp-1.9 Consequently, Blimp-1 may
initially allow VEGF expression, which is then regulated by modifying
factors in vivo. Perhaps VEGF expression by plasma cells in the
E/P
Plasma cells up-regulate antiapoptotic factors, including Bcl-xL, Bcl-w, and XIAP, but lose Bcl-2 In accordance with other categories of genes, many more genes associated with apoptosis were lost rather than gained in plasma cells (Table 4). For example, Bcl-2 expression was lost in plasma cells. However, 2 other Bcl-2 family members, Bcl-xL and Bcl-w, were up-regulated in plasma cells 2.1-fold and 4.8-fold, respectively (Table 4). The higher expression of Bcl-xL versus Bcl-2 was reported previously in human plasma cells.50 Additionally, several proapoptotic factors were lost or down-regulated in plasma cells, including, among others, the Bcl-2 family member BID, the Bcl-2 binding protein Bax, and caspases 6 and 2 (Table 4). Another factor that has been associated with B-cell survival is the Pim-1 kinase.51 Interestingly, although Pim-1 kinase activity in B cells has been attributed to BCR activation, CD40 signaling, or lipopolysaccharide (LPS) stimulation,51 the microarray analysis demonstrated a 21.2-fold up-regulation in Pim-1 expression in plasma cells (Figure 4), which have lost CD40 and multiple BCR signaling components (Table 5 and Figure 4). However, Pim-1 can also be induced by Stat3-mediated transcription through gp130 signaling,52 a pathway that is retained in plasma cells (mentioned above). Furthermore, valosine-containing protein (VCP), which is a target of Pim-1 signaling and involved in Pim-1-mediated protection against apoptosis,52 is up-regulated in plasma cells 2.9-fold (Table 4). An up-regulation of Pim-1 mRNA expression in plasma cells was also confirmed by quantitiative RT-PCR (Table 1). Consequently, Pim-1 kinase expression resulting from IL-6 signaling and Stat3 activation may be a critical component in the protection of plasma cells against apoptosis.
Recently, the induction of GADD45 Plasma cells express the nervous system genes, reelin and neuropilin Select additional alterations in plasma cell gene expression are displayed in Table 5. Unexpectedly, the plasma cells expressed factors that have previously been associated with nervous system function. One such gene that was highly induced in plasma cells encodes the protein reelin (Table 5), which regulates the migration of neurons in the developing cortex and is mutated in the reeler mouse strain.59 The induction of reelin in plasma cells was confirmed by quantitative RT-PCR (Figure 3A and Table 1). Receptors for reelin include the very low density lipoprotein receptor (Vldlr), the apolipoprotein E receptor-2 (ApoER2), and the integrin31. ApoE
can block receptor binding of reelin and subsequent
signaling60 and, interestingly, ApoE expression was lost
in the plasma cells examined here (Table 5). In contrast, mRNA for ApoE
has been reported previously to be expressed by bone marrow plasma
cells and significantly down-regulated in myeloma.42
Consequently, the expression shift from ApoE to reelin upon plasma cell
differentiation may be important in regulating the migration of plasma
cells or an associated cell type with which plasma cells interact
within distinct anatomic sites. Further analysis into reelin expression by plasma cells could provide insight into additional physiological roles of reelin and the possibility that analogous to its function in
the nervous system, reelin could function in cell positioning within
lymphoid organs.
Another factor up-regulated in plasma cells that plays an important role in the organization of cells within the nervous system was neuropilin-1 (Table 5),61,62 and this up-regulation was also confirmed by quantitative RT-PCR (Figure 3A and Table 1). Neuropilin-1 has also been shown to bind VEGF and modulate VEGF signaling through the VEGF receptor, KDR.63 Recently, neuropilin-1 was shown to be expressed by dendritic cells and resting T cells and to be involved in a homotypic interaction between these 2 cell types, suggesting that neuropilin-1 plays a role in the initiation of the immune response.64 Furthermore, neuropilin-1 expression was described in bone marrow stromal cell lines as well as bone marrow adherent cells.65 Collectively, these findings strongly suggest that neuropilin-1 may be involved in positioning of plasma cells within appropriate bone marrow microenvironments. In summary, by utilizing oligonucleotide microarray analysis of primary plasma cells and B cells, we have demonstrated that plasma cells exhibit multiple genetic alterations specific to plasma cell differentiation. The plasma cells displayed a unique pattern of expression of transcription factors, signaling molecules, as well as genes involved in the regulation of proliferation and apoptosis. Additionally, the comparison of plasma cells and B cells provides important information regarding not only gene expression alterations but also genes that are selectively retained during plasma cell differentiation. In conclusion, these results provide insight into the gene expression changes underlying the mechanisms of plasma cell terminal differentiation and the factors that govern plasma cell function in vivo. Furthermore, the plasma cell profile of gene expression described here provides a solid foundation for future research into plasma cell biology.
We thank Dr Susan Winandy for critical review of this manuscript.
Submitted September 3, 2002; accepted January 7, 2003.
Prepublished online as Blood First Edition Paper, January 23, 2003; DOI 10.1182/blood- 2002-08-2673.
Supported by National Institutes of Health grant HL58710 (G.S.K.). The microarray facility at the Children's Memorial Institute of Education and Research is supported by the Falk Foundation.
The online version of the article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Geoffrey S. Kansas, Department of Microbiology-Immunology, Northwestern Medical School, 303 E Chicago Ave, Chicago, IL 60611; e-mail: gsk{at}northwestern.edu.
1. Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001;412:300-307[CrossRef][Medline] [Order article via Infotrieve]. 2. Turner C Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell. 1994;77:297-306[CrossRef][Medline] [Order article via Infotrieve].
3.
Angelin-Duclos C, Cattoretti G, Lin KL, Calame K.
Commitment of B lymphocytes to a plasma cell fate is associated with blimp-1 expression in vivo.
J Immunol.
2000;165:5462-5471
4.
Mittrucker HW, Matsuyama T, Grossman A, et al.
Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function.
Science.
1997;275:540-543 5. Usui T, Wakatsuki Y, Matsunaga Y, et al. Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. J Immunol. 1997;158:3197-3204[Abstract].
6.
Reimold AM, Ponath PD, Li YS, et al.
Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1.
J Exp Med.
1996;183:393-401 7. Shaffer AL, Yu X, He Y, Boldnek J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13:199-212[CrossRef][Medline] [Order article via Infotrieve].
8.
Lin K-I, Angelin-Duclos C, Kuo TC, Calame K.
Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to IgM secreting plasma cells.
Mol Cell Biol.
2002;22:4771-4780 9. Shaffer AL, Lin K-I, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002;17:51-62[CrossRef][Medline] [Order article via Infotrieve].
10.
Bullard DC, Kunkel EJ, Kubo H, et al.
Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E-selectin and P-selectin double mutant mice.
J Exp Med.
1996;183:2329-2337
11.
Underhill GH, Minges Wols HA, Fornek JL, Witte PL, Kansas GS.
IgG plasma cells display a unique spectrum of leukocyte adhesion and homing molecules.
Blood.
2002;99:2905-2912
12.
Mayanil CSK, George D, Freilich L, et al.
Microarray analysis detects novel Pax3 downstream target genes.
J Biol Chem.
2001;276:49299-49309 13. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol. 2001;2:1103-1108[CrossRef][Medline] [Order article via Infotrieve]. 14. Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol. 2000;1:526-532[CrossRef][Medline] [Order article via Infotrieve].
15.
Lin Y, Wong K, Calame K.
Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation.
Science.
1997;276:596-599
16.
Vasanwala FH, Kusam S, Toney LM, Dent AL.
Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene.
J Immunol.
2002;169:1922-1929
17.
Ghosh S, Karin M.
Missing pieces in the NF-
18.
Doerre S, Corley RB.
Constitutive nuclear translocation of NF- 19. Peng SL, Gerth AJ, Ranger AM, Glimcher LH. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity. 2001;14:13-20[CrossRef][Medline] [Order article via Infotrieve]. 20. Ranger AM, Oukka M, Rengarajan J, Glimcher LH. Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Immunity. 1998;9:627-635[CrossRef][Medline] [Order article via Infotrieve]. 21. Luscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene. 2001;277:1-14[CrossRef][Medline] [Order article via Infotrieve].
22.
Lin KI, Lin Y, Calame K.
Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro.
Mol Cell Biol.
2000;20:8684-8695 23. Matthias P. Lymphoid-specific transcription mediated by the conserved octamer site: who is doing what? Semin Immunol. 1998;10:155-163[CrossRef][Medline] [Order article via Infotrieve]. 24. Corcoran LM, Karvelas M. Oct-2 is required early in T cell-independent B cell activation for G1 progression and for proliferation. Immunity. 1994;1:635-645[CrossRef][Medline] [Order article via Infotrieve]. 25. Schubart K, Massa S, Schubart D, Corcoran LM, Rolink AG, Matthias P. B cell development and immunoglobulin gene transcription in the absence of Oct-2 and OBF-1. Nat Immunol. 2001;2:69-74[CrossRef][Medline] [Order article via Infotrieve].
26.
Veenstra GJ, Weeks DL, Wolffe AP.
Distinct roles for TBP and TBP-like factor in early embryonic gene transcription in Xenopus.
Science.
2000;290:2312-2315
27.
Alzuherri HM, White RJ.
Regulation of RNA polymerase I transcription in response to F9 embryonal carcinoma stem cell differentiation.
J Biol Chem.
1999;274:4328-4334
28.
Larson DE, Xie W, Glibetic M, O'Mahony D, Sells BH, Rothblum LI.
Coordinated decreases in rRNA gene transcription factors and rRNA synthesis during muscle cell differentiation.
Proc Natl Acad Sci U S A.
1993;90:7933-7936
29.
Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF.
Irs-2 coordinates Igf-1 receptor-mediated
30.
Wang HY, Zamorano J, Keegan AD.
A role for the insulin-interleukin (IL)-4 receptor motif of the IL-4 receptor
31.
Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K.
Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines.
Blood.
1996;88:2250-2258 32. Nicholson SE, Willson TA, Farley A, et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 1999;18:375-385[CrossRef][Medline] [Order article via Infotrieve]. 33. Starr R, Wilson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917-921[CrossRef][Medline] [Order article via Infotrieve].
34.
Ndubuisi MI, Guo GG, Fried VA, Etlinger JD, Sehgal PB.
Cellular physiology of STAT3: where's the cytoplasmic monomer?
J Biol Chem.
1999;274:25499-25509
35.
Minges Wols HA, Underhill GH, Kansas GS, Witte PL.
The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity.
J Immunol.
2002;169:4213-4221 36. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995;64:621-651[Medline] [Order article via Infotrieve].
37.
Costa-Pereira AP, Tininini S, Strobl B, et al.
Mutational switch of an IL-6 response to an interferon-
38.
Aberle H, Bauer A, Stappert J, Kispert A, Kemler R.
39. van de Wetering M, de Lau W, Clevers H. WNT signaling and lymphocyte development. Cell. 2002;109:S13-S19[CrossRef][Medline] [Order article via Infotrieve]. 40. Yost C, Farr GH III, Pierce SB, Ferkey DM, Chen MM, Kimelman D. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell. 1998;93:1031-1041[CrossRef][Medline] [Order article via Infotrieve]. 41. Li L, Yuan H, Weaver CD, et al. Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J. 1999;18:4233-4240[CrossRef][Medline] [Order article via Infotrieve].
42.
Zhan F, Hardin J, Kordsmeier B, et al.
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Blood.
2002;99:1745-1757 43. Moloney DJ, Panin VM, Johnston SH, et al. Fringe is a glycosyltransferase that modifies Notch. Nature. 2000;406:369-375[CrossRef][Medline] [Order article via Infotrieve]. 44. Bruckner K, Perez L, Clausen H, Cohen S. Glycosyltransferase activity of Fringe modulates Notch-Delta interactions. Nature. 2000;406:357-358[CrossRef][Medline] [Order article via Infotrieve]. 45. Allman D, Punt JA, Izon DJ, Aster JC, Pear WS. An invitation to T and more: notch signaling in lymphopoiesis. Cell. 2002;109:S1-S11[CrossRef][Medline] [Order article via Infotrieve].
46.
Herreman A, Hartmann D, Annaert W, et al.
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency.
Proc Natl Acad Sci U S A.
1999;96:11872-11877
47.
Alves da Costa C, Paitel E, Mattson MP, et al.
Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons.
Proc Natl Acad Sci U S A.
2002;99:4043-4048
48.
Podar K, Tai Y-T, Davies FE, et al.
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Blood.
2001;98:428-435 49. Nishi J, Arimura K, Utsunomiya A, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol. 1999;104:482-485[CrossRef][Medline] [Order article via Infotrieve].
50.
Krajewski S, Krajewska M, Shabaik A, et al.
Immunohistochemical analysis of in vivo patterns of bcl-x expression.
Cancer Res.
1994;54:5501-5507
51.
Zhu N, Ramirez LM, Lee RL, Magnuson NS, Bishop GA, Gold MR.
CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF- 52. Shirogane T, Fukada T, Muller JMM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-myc in Stat3-mediated cell cycle progression and antiapoptosis. Immunity. 1999;11:709-719[CrossRef][Medline] [Order article via Infotrieve].
53.
De Smaele E, Zazzeroni F, Papa S, et al.
Induction of gadd45
54.
Jin R, De Smaele E, Zazzeroni F, et al.
Regulation of the gadd45
55.
Tang G, Minemoto Y, Dibling B, et al.
Inhibition of JNK activation through NF-
56.
Hideshima T, Chauhan D, Richardson P, et al.
NF-
57.
Chauhan D, Kharbanda S, Ogata A, et al.
Interleukin-6 inhibits fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.
Blood.
1997;89:227-234
58.
Xu FH, Sharma S, Gardner A, et al.
Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway.
Blood.
1998;92:241-251 59. Rice DS, Curran T. Role of the reelin signaling pathway in central nervous system development. Annu Rev Neurosci. 2001;24:1005-1039[CrossRef][Medline] [Order article via Infotrieve]. 60. D'Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T. Reelin is a ligand for lipoprotein receptors. Neuron. 1999;24:471-479[CrossRef][Medline] [Order article via Infotrieve]. 61. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell. 1997;90:753-762[CrossRef][Medline] [Order article via Infotrieve]. 62. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell. 1997;90:739-751[CrossRef][Medline] [Order article via Infotrieve]. 63. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92:735-745[CrossRef][Medline] [Order article via Infotrieve]. 64. Tordjman R, Lepelletier Y, Lemarchandel V, et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol. 2002;3:477-482[Medline] [Order article via Infotrieve].
65.
Tordjman R, Ortega N, Coulombel L, Plouet J, Romeo PH, Lemarchandel V.
Neuropilin-1 is expressed on bone marrow stromal cells: a novel interaction with hematopoietic cells?
Blood.
1999;94:2301-2309
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. E. Khuda, W. M. Loo, S. Janz, B. Van Ness, and L. D. Erickson Deregulation of c-Myc Confers Distinct Survival Requirements for Memory B Cells, Plasma Cells, and Their Progenitors J. Immunol., December 1, 2008; 181(11): 7537 - 7549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Watanabe, G. L. Shu, T. S. Zheng, R. A. Flavell, and E. A. Clark Caspase 6 Regulates B Cell Activation and Differentiation into Plasma Cells J. Immunol., November 15, 2008; 181(10): 6810 - 6819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Shell, K. Martincic, J. Tran, and C. Milcarek Increased Phosphorylation of the Carboxyl-Terminal Domain of RNA Polymerase II and Loading of Polyadenylation and Cotranscriptional Factors Contribute to Regulation of the Ig Heavy Chain mRNA in Plasma Cells J. Immunol., December 1, 2007; 179(11): 7663 - 7673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. L. Oliveira, P. Frazao, R. Chammas, D. K. Hsu, F. T. Liu, R. Borojevic, C. M. Takiya, and M. C. El-Cheikh Kinetics of mobilization and differentiation of lymphohematopoietic cells during experimental murine schistosomiasis in galectin-3 / mice J. Leukoc. Biol., August 1, 2007; 82(2): 300 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Minges Wols, J. A. Ippolito, Z. Yu, J. L. Palmer, F. A. White, P. T. Le, and P. L. Witte The effects of microenvironment and internal programming on plasma cell survival Int. Immunol., July 2, 2007; (2007) dxm051v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L.M. Boylan, M. A. Gosse, S. E. Staggs, S. Janz, S. Grindle, G. S. Kansas, and B. G. Van Ness A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple Myeloma Cancer Res., May 1, 2007; 67(9): 4069 - 4078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Kuo, A. L. Shaffer, J. Haddad Jr., Y. S. Choi, L. M. Staudt, and K. Calame Repression of BCL-6 is required for the formation of human memory B cells in vitro J. Exp. Med., April 16, 2007; 204(4): 819 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chiu, A. G. Heaps, V. Cerundolo, A. J. McMichael, C. R. Bangham, and M. F. C. Callan Early acquisition of cytolytic function and transcriptional changes in a primary CD8+ T-cell response in vivo Blood, February 1, 2007; 109(3): 1086 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Abrams, T. Lakum, K. Lin, G. M. Jones, A. T. Treweeke, M. Farahani, M. Hughes, M. Zuzel, and J. R. Slupsky B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase C{beta}II Blood, February 1, 2007; 109(3): 1193 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Renne, J. I. Martin-Subero, M. Eickernjager, M.-L. Hansmann, R. Kuppers, R. Siebert, and A. Brauninger Aberrant Expression of ID2, a Suppressor of B-Cell-Specific Gene Expression, in Hodgkin's Lymphoma Am. J. Pathol., August 1, 2006; 169(2): 655 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Fornek, L. T. Tygrett, T. J. Waldschmidt, V. Poli, R. C. Rickert, and G. S. Kansas Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells Blood, February 1, 2006; 107(3): 1085 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Underhill, D. G. Zisoulis, K. P. Kolli, L. G. Ellies, J. D. Marth, and G. S. Kansas A crucial role for T-bet in selectin ligand expression in T helper 1 (Th1) cells Blood, December 1, 2005; 106(12): 3867 - 3873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lotz, S. A. Mutallib, N. Oehlrich, U. Liewer, E. A. Ferreira, M. Moos, M. Hundemer, S. Schneider, S. Strand, C. Huber, et al. Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL J. Immunol., July 15, 2005; 175(2): 1301 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Q. Zhang, C. Okumura, T. McCarty, M. S. Shin, P. Mukhopadhyay, M. Hori, T. A. Torrey, Z. Naghashfar, J. X. Zhou, C. H. Lee, et al. Evidence for Selective Transformation of Autoreactive Immature Plasma Cells in Mice Deficient in Fasl J. Exp. Med., December 6, 2004; 200(11): 1467 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Welch, J. A. Watts, C. R. Vakoc, Y. Yao, H. Wang, R. C. Hardison, G. A. Blobel, L. A. Chodosh, and M. J. Weiss Global regulation of erythroid gene expression by transcription factor GATA-1 Blood, November 15, 2004; 104(10): 3136 - 3147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Ebert and T. R. Golub Genomic approaches to hematologic malignancies Blood, August 15, 2004; 104(4): 923 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sciammas and M. M. Davis Modular Nature of Blimp-1 in the Regulation of Gene Expression during B Cell Maturation J. Immunol., May 1, 2004; 172(9): 5427 - 5440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Podar, L. P. Catley, Y.-T. Tai, R. Shringarpure, P. Carvalho, T. Hayashi, R. Burger, R. L. Schlossman, P. G. Richardson, L. N. Pandite, et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment Blood, May 1, 2004; 103(9): 3474 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Jundt, K. S. Probsting, I. Anagnostopoulos, G. Muehlinghaus, M. Chatterjee, S. Mathas, R. C. Bargou, R. Manz, H. Stein, and B. Dorken Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells Blood, May 1, 2004; 103(9): 3511 - 3515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. O'Connor, V. S. Raman, L. D. Erickson, W. J. Cook, L. K. Weaver, C. Ahonen, L.-L. Lin, G. T. Mantchev, R. J. Bram, and R. J. Noelle BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells J. Exp. Med., January 5, 2004; 199(1): 91 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Underhill, K. P. Kolli, and G. S. Kansas Complexity within the plasma cell compartment of mice deficient in both E- and P-selectin: implications for plasma cell differentiation Blood, December 1, 2003; 102(12): 4076 - 4083. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
B (NF-
terminally differentiated plasma cells as well as
the distinct adhesion characteristics of these
cells.
) versus IgM+ B cells (
) by
real-time quantitative RT-PCR are shown. 